Connection
Daniel Pollyea to Immunotherapy, Adoptive
This is a "connection" page, showing publications Daniel Pollyea has written about Immunotherapy, Adoptive.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.964 |
|
|
|
-
Pollyea D, Kerre T, Deeren D, Beguin Y, Lin TL, Sallman DA, Anguille S, Blum WG, Flament A, Breman E, Lonez C. Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia. Leukemia. 2025 12; 39(12):2907-2915.
Score: 0.704
-
Kent A, Pollyea DA. Top advances of the year: Leukemia. Cancer. 2023 04 01; 129(7):981-985.
Score: 0.146
-
Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019 06; 74:52-63.e3.
Score: 0.114